ARTICLE | Company News
Amgen, Biovitrum deal
December 22, 2008 8:00 AM UTC
Biovitrum completed its previously announced acquisition of Amgen's marketed products Kepivance palifermin and Stemgen ancestim for $97 million in cash and about 3.8 million Biovitrum shares valued ...